Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma

British Journal of Haematology

Volumn 143, Issue 2, 2008, Pages 268-273

  Costa, Luciano J ^a   Micallef, Ivana N ^a   Inwards, David J ^a   Johnston, Patrick B ^a   Porrata, Luis F ^a   Litzow, Mark R ^a   Ansell, Stephen M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Body surface area; Chemotherapy; Diffuse; Large B cell; Lymphoma; Mucositis; Stem cell transplantation

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; MELPHALAN; PALIFERMIN; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BODY SURFACE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DOSE CALCULATION; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LENGTH OF STAY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CARMUSTINE; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENGTH OF STAY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MELPHALAN; MIDDLE AGED; MUCOSITIS; RECURRENCE; RISK; STATISTICS, NONPARAMETRIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 52649112109     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07342.x     Document Type: Article

References (27)

1. Blijlevens, N., Schwenkglenks, M., Bacon, P., D'Addio, A., Einsele, H., Maertens, J., Niederwieser, D., Rabitsch, W., Roosaar, A., Ruutu, T., Schouten, H., Stone, R., Vokurka, S., Quinn, B. McCann, S. (2008) Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. Journal of Clinical Oncology, 26, 1519 1525.
2. Buadi, F.K., Micallef, I.N., Ansell, S.M., Porrata, L.F., Dispenzieri, A., Elliot, M.A., Gastineau, D.A., Gertz, M.A., Lacy, M.Q., Litzow, M.R., Tefferi, A. Inwards, D.J. (2006) Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplantation, 37, 1017 1022.
3. Caballero, M.D., Rubio, V., Rifon, J., Heras, I., Garcia-Sanz, R., Vazquez, L., Vidriales, B., del Canizo, M.C., Corral, M., Gonzalez, M., Leon, A., Jean-Paul, E., Rocha, E., Moraleda, J.M. San Miguel, J.F. (1997) BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplantation, 20, 451 458.
4. Costa, L.J., Micallef, I.N., Inwards, D.J., Johnston, P.B., Porrata, L.F. Ansell, S.M. (2008) Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 41, 715 720.
5. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117 4126.
6. Gaspard, M.H., Maraninchi, D., Stoppa, A.M., Gastaut, J.A., Michel, G., Tubiana, N., Blaise, D., Novakovitch, G., Rossi, J.F., Weiller, P.J., Sainty, D., Horchowski, N. Carcassonne, Y. (1988) Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemotherapy and Pharmacology, 22, 256 262.
7. Grazziutti, M.L., Dong, L., Miceli, M.H., Krishna, S.G., Kiwan, E., Syed, N., Fassas, A., van Rhee, F., Klaus, H., Barlogie, B. Anaissie, E.J. (2006) Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplantation, 38, 501 506.
8. Guglielmi, C., Gomez, F., Philip, T., Hagenbeek, A., Martelli, M., Sebban, C., Milpied, N., Bron, D., Cahn, J.Y., Somers, R., Sonneveld, P., Gisselbrecht, C., Van Der Lelie, H. Chauvin, F. (1998) Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. Journal of Clinical Oncology, 16, 3264 3269.
9. Gurney, H. (2002) How to calculate the dose of chemotherapy. British Journal of Cancer, 86, 1297 1302.
10. Gutierrez, M., Chabner, B.A., Pearson, D., Steinberg, S.M., Jaffe, E.S., Cheson, B.D., Fojo, A. Wilson, W.H. (2000) Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. Journal of Clinical Oncology, 18, 3633 3642.
11. Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 3121 3127.
12. Hamlin, P.A., Zelenetz, A.D., Kewalramani, T., Qin, J., Satagopan, J.M., Verbel, D., Noy, A., Portlock, C.S., Straus, D.J., Yahalom, J., Nimer, S.D. Moskowitz, C.H. (2003) Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 102, 1989 1996.
13. Khouri, I.F., Saliba, R.M., Hosing, C., Okoroji, G.J., Acholonu, S., Anderlini, P., Couriel, D., De Lima, M., Donato, M.L., Fayad, L., Giralt, S., Jones, R., Korbling, M., Maadani, F., Manning, J.T., Pro, B., Shpall, E., Younes, A., McLaughlin, P. Champlin, R.E. (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology, 23, 2240 2247.
14. Moskowitz, C.H., Nimer, S.D., Glassman, J.R., Portlock, C.S., Yahalom, J., Straus, D.J., O'Brien, J.P., Elkin, N., Bertino, J.R. Zelenetz, A.D. (1999) The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplantation, 23, 561 567.
15. Navarro, W.H., Loberiza, Jr., F.R., Bajorunaite, R., van Besien, K., Vose, J.M., Lazarus, H.M. Rizzo, J.D. (2006) Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 12, 541 551.
16. Page, R.L., Macy, D.W., Thrall, D.E., Dewhirst, M.W., Allen, S.L., Heidner, G.L., Sim, D.A., McGee, M.L. Gillette, E.L. (1988) Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog. Cancer Research, 48, 288 290.
17. Peterson, D.E. Cariello, A. (2004) Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Seminars in Oncology, 31, 35 44.
18. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology, 7, 379 391.
19. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y., Harousseau, J.L., Coiffier, B., Biron, P., Mandelli, F. Chauvin, F. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540 1545.
20. Prince, H.M., Imrie, K., Crump, M., Stewart, A.K., Girouard, C., Colwill, R., Brandwein, J., Tsang, R.W., Scott, J.G., Sutton, D.M., Pantalony, D., Carstairs, K., Sutcliffe, S.B. Keating, A. (1996) The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. British Journal Haematology, 92, 880 889.
21. Puig, N., de la Rubia, J., Remigia, M.J., Jarque, I., Martin, G., Cupelli, L., Sanz, G.F., Lorenzo, I., Sanz, J., Martinez, J.A., Jimenez, C. Sanz, M.A. (2006) Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leukaemia & Lymphoma, 47, 1488 1494.
22. Sonis, S.T., Oster, G., Fuchs, H., Bellm, L., Bradford, W.Z., Edelsberg, J., Hayden, V., Eilers, J., Epstein, J.B., LeVeque, F.G., Miller, C., Peterson, D.E., Schubert, M.M., Spijkervet, F.K. Horowitz, M. (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. Journal of Clinical Oncology, 19, 2201 2205.
23. Spielberger, R., Stiff, P., Bensinger, W., Gentile, T., Weisdorf, D., Kewalramani, T., Shea, T., Yanovich, S., Hansen, K., Noga, S., McCarty, J., LeMaistre, C.F., Sung, E.C., Blazar, B.R., Elhardt, D., Chen, M.G. Emmanouilides, C. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. New England Journal of Medicine, 351, 2590 2598.
24. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood, 89, 3909 3918.
25. Velasquez, W.S., Cabanillas, F., Salvador, P., McLaughlin, P., Fridrik, M., Tucker, S., Jagannath, S., Hagemeister, F.B., Redman, J.R. Swan, F. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood, 71, 117 122.
26. Vose, J.M., Anderson, J.R., Kessinger, A., Bierman, P.J., Coccia, P., Reed, E.C., Gordon, B. Armitage, J.O. (1993) High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 11, 1846 1851.
27. Vose, J.M., Bierman, P.J., Enke, C., Hankins, J., Bociek, G., Lynch, J.C. Armitage, J.O. (2005) Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 461 467.